Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Particulate form
Reexamination Certificate
2000-09-25
2002-09-10
Spear, James M. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Particulate form
C424S433000, C424S436000, C424S464000, C424S451000, C424S455000, C424S489000, C514S937000, C514S944000, C514S951000, C514S952000, C514S969000, C514S970000
Reexamination Certificate
active
06447806
ABSTRACT:
This invention relates to particles of biologically active substances that are electrostatically protected against coagulation when they are dispersed in water, e.g. producing colloids, and pharmaceutical compositions containing them.
Biologically active substances are understood to include those active substances, i.e. pharmacologically active substances, which may be used in medicine as medicaments or in the agricultural industry e.g. as pesticides. The term “biological compositions” therefore also includes compositions which are employed in the agricultural industry. However, the invention relates in particular to pharmaceutical compositions for medicinal usage.
Colloids produced on dispersing the particles may have in general a particle size of between 1 and 10000 nanometers (=0.001 to 10 micrometers). These colloidal particles in compositions of the present invention are believed to consist only of active substance in amorphous form. The small size of the particles, especially less than 2 micrometers, enables intravenous application of the colloidal drug particles to take place without any danger of blocking the finest blood capillaries.
The colloidal state in itself is generally regarded as unstable and liable to collapse since this finely-dispersed state is associated with a large surface area. The colloidal system attempts to;reduce the surface area in the dispersion medium by coagulation,: e.g. aggregation, flocculation or crystallization. Addition of stabilizers is necessary to prevent this.
Basically, there are two known principles of stabilization. The first is steric stabilization. Polymer molecules are adsorbed on the surface of the particles and prevent aggregation or flocculation through their chains which reach into the dispersion medium.
The second principle is based on charging particles positively or negatively and on the resulting reciprocal repulsion of the particles. The stabilizer is charged and contains a lipophilic moiety which is suitable for adsorption onto the lipophilic surface of the particles. Since the potential prevailing at the particle surface is poorly accessible for technical measurement, the so-called zeta potential has become is a well known characteristic used e.g. to indicate the stability of electro-statically stabilized particles. The zeta potential of an electrostatically stabilized particle may be regarded as the electric potential prevailing at its boundary surface, corresponding to a layer at a certain distance from the particle up to which electrolyte ions in solution are brought or from which they are removed by thermal motion.
The zeta potentials may be determined in conventional manner, e.g. as described in example 3 hereinafter.
The present invention provides in one aspect particles of a substantially water insoluble biologically active substance having on the surface thereof charged glyceryl ester, the particles having an active substance: ester weight ratio of from 1:1 to 400:1.
In another aspect the invention provides pharmaceutical compositions comprising particles of a biologically active substance which is very poorly soluble in water and which are free from polymeric or cross linked nucleus, wall or matrix material, but loaded with a negatively or positively charged glyceryl ester as an electrostatic stabilizer which imparts to the particles a zeta potential of −1.5 to −100 or from +1.5 to +100 mV when in an aqueous 0.01 molar KCl solution, the particles having an active substance: stabilizer weight ratio of 1:1 to 400:1 and having diameters of 1 nanometer to 10 micrometers when measured in a liquid medium.
The present invention also provides a process for the production of particles according to the invention which comprises mixing a) an organic solution containing 1 to 100 mg/ml pharmacologically active substance and the glyceryl ester or electrostatic stabilizer and b) an aqueous medium are under conditions such that in the corresponding mixture the weight ratio of active substance to ester or stabilizer corresponds to that given above.
In a further aspect the present invention provides a process for the production of a pharmaceutical composition according to the invention wherein in a first step the particles are produced, with subsequent isolation of the resultant colloidal particles.
The glyceryl esters preferably have organic and inorganic acid moieties. The organic acid moiety is preferably of a fatty acid. The inorganic acid moiety is preferably derived from a polybasic acid, e.g. phosphoric acid. Additionally, the glyceryl esters may contain amino residues, e.g. amino alcohol ester residues, or hydroxyl residues, e.g. glycerol.
The organic acid moiety is the lipophilic moiety of the glyceryl ester; the inorganic acid moiety may, if in salt form, give the glyceryl ester molecule its negative charge; the amino moiety, if present, may, if quaternized, give the glyceryl ester molecule a positive charge.
A preferred class of glyceryl esters are the negatively and positively charged phospholipids.
The biologically active substances are preferably those which may be employed in medicine.
Preferably their water solubility is less than 1 part by weight of substance per 1000 parts by volume of water (=0.1% or 1
mg
/ml at room temperature).
Such substances are classified according to USP XXII (1990) as very poorly (slightly) soluble.
The water solubility is preferably at least 1 part by volume of substance per 10000 parts by volume of water (=0.01% or 0.1
mg
/ml).
The active substances may belong to any of a wide variety of chemical classes. One example of an active substance are the imidazoles. Another Example is FK 506. This compound has been described in Merck Index, Eleventh Edition, Appendix, A5. Analogues of FK 506 are also generally known. The active substances are preferably very poorly soluble peptides, especially cyclopeptides, such as those having cyclosporin structure, such as the cyclosporins, especially those having a water solubility of at most 400, especially at most 40, micro-grams per ml of water. The cyclosporins comprise a known class of pharmacologically active substances, which are described extensively together with their medicinal uses in the literature see e.g. GB 2,222,770 A (the contents of which are incorporated by reference). Preferred cyclosporins are cyclosporin A (=ciclosporin), cyclosporin G (see Example 3), cyclosporin D and the other cyclosporins mentioned in Example 3.
REFERENCES:
patent: 4145410 (1979-03-01), Sears
patent: 4271196 (1981-06-01), Schmidt
patent: RE31609 (1984-06-01), Sears
patent: 4486417 (1984-12-01), Sugimoto et al.
patent: 4826689 (1989-05-01), Violanto et al.
patent: 4839111 (1989-06-01), Huang
patent: 4876086 (1989-10-01), Dowrick
patent: 4902500 (1990-02-01), Jansen et al.
patent: 4960814 (1990-10-01), Wu et al.
patent: 4963297 (1990-10-01), Madden
patent: 4963362 (1990-10-01), Rahman et al.
patent: 4990337 (1991-02-01), Kurihara et al.
patent: 5000959 (1991-03-01), Iga et al.
patent: 5002940 (1991-03-01), Geller et al.
patent: 5025004 (1991-06-01), Wu et al.
patent: 5110475 (1992-05-01), Rössling et al.
patent: 5152923 (1992-10-01), Weder et al.
patent: 5283067 (1994-02-01), Geller et al.
patent: 0 169 618 (1986-01-01), None
patent: 0 220 153 (1987-04-01), None
patent: 0 220 797 (1987-05-01), None
patent: 0 261 802 (1988-03-01), None
patent: 0 274 431 (1988-07-01), None
patent: 0 276 911 (1988-08-01), None
patent: 0 296 845 (1988-12-01), None
patent: 0 361 928 (1990-04-01), None
patent: 0 391 369 (1990-10-01), None
patent: 0 429 428 (1991-05-01), None
patent: 1 532 993 (1976-02-01), None
patent: 2 200 048 (1988-07-01), None
patent: 2 201 089 (1988-08-01), None
patent: 2 230 440 (1990-10-01), None
patent: 63072678 (1988-02-01), None
patent: WO 88/06438 (1988-09-01), None
patent: 88/06438 (1988-09-01), None
S. Benita, et al., vol. 73, No. 12, 1751-1755 (1984).
Bensouda, et al,. Lab de Phar. Galén. et de Biophar., 241-250, France (undated). (+Translation).
Chem. Abst., 125896h, vol. 106, 399 (1987).
Ch
Gassmann Peter
Sucker Heinz
Lopez Gabriel
Novartis AG
Spear James M.
LandOfFree
Pharmaceutical compositions comprised of stabilized peptide... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions comprised of stabilized peptide..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions comprised of stabilized peptide... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2833849